Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells

Mercedes Salido,1 Juan L. Gonzalez,2 and Jose Vilches1

Departments of 1Histology and 2Statistics and Operational Research, School of Medicine, University of Cadiz, Cádiz, Spain

Abstract
Neuroendocrine secretory products and their interactions with epithelial prostate cells are currently under investigation in order to understand their significance in the pathogenesis, prognosis, and therapy of prostate carcinoma. These neuropeptides have the potential to disrupt the balance between cell death and cell growth in the tumor. Our research was based on the role of bombesin in modulating the mitochondrial membrane potential ($\Delta \psi_m$) in cell death induced by etoposide on PC-3 cells. Cells were cultured and stained with 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolecarbocyanine iodide (JC-1). At low membrane potentials, JC-1 produces a green fluorescence, and at high membrane potentials, it forms "J aggregates" with red fluorescence. Cells were examined in a confocal microscope. For quantitative analyses, regions of interest were selected. The size, number of pixels, and ratios between fluorescence intensity in the red and green channels in each region of interest were calculated. The loss of $\Delta \psi_m$ in etoposide-treated PC-3 cells was prevented by bombesin. The quantitative analysis of JC-1–stained cells revealed a significant decrease in the red (high $\Delta \psi_m$) to green (low $\Delta \psi_m$) ratio in etoposide-treated cells when compared with control cells, which was restored in the presence of bombesin ($P < 0.00001$). The interaction between treatments and area ($P = 0.0002$) was highly significant, and confirms that PC-3 cells keep their apoptosis machinery, showing an apoptotic volume decrease in response to etoposide. The protection by bombesin occurs by inhibition of apoptosis and maintenance of mitochondrial integrity. New therapeutic protocols and trials need to be developed to test drugs acting through the neutralization of antiapoptotic intracellular pathways mediated by neuroendocrine hormones. [Mol Cancer Ther 2007;6(4):1292–9]

Introduction
Neuroendocrine differentiation in prostatic adenocarcinomas has received increasing attention in recent years as a result of possible implications in prognosis and therapy (1-4). Neuroendocrine secretory products and their interactions with epithelial prostate cells are currently under investigation in order to understand their significance in the pathogenesis, prognosis, and therapy of prostate gland carcinoma (5-8). Recently, we showed that bombesin inhibits etoposide-induced apoptosis in human androgen-independent prostatic cancer cell lines (9); thus, these neuropeptides could disrupt the balance between cell death and cell growth in the tumor.

The most relevant biological interest in apoptosis is the possibility of its modulation, hence, the identification of inductive and protective factors and their mechanisms of action seem to be the most relevant challenges in apoptosis research. The increasing number of studies enforcing the importance of mitochondria in apoptosis signaling, with an increase in complexity, has resulted in a strong debate concerning the exact sequence of mitochondrial events. Mitochondrial dysfunction in apoptosis is related with specific permeabilization of the outer mitochondrial membrane to large molecules including ions that are relevant in the apoptotic process (10). The detection of the mitochondrial permeability transition event provides an early indication of the initiation of cellular apoptosis. This process is typically defined as a collapse in the electrochemical gradient across the mitochondrial membrane, as measured by the change in the mitochondrial membrane potential ($\Delta \psi$). Loss of mitochondrial $\Delta \psi$, indicative of apoptosis, can be detected by a unique fluorescent cationic dye, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide, commonly known as JC-1. JC-1 is a cationic dye that exhibits potential-dependent accumulation in mitochondria, indicated by a fluorescence emission shift from green (~525 nm) to red (~590 nm). Consequently, mitochondrial depolarization is indicated by a decrease in the red/green fluorescence intensity ratio. The potential-sensitive color shift is due to the concentration-dependent formation of red fluorescent "J aggregates" (11). Therefore, a careful analysis of the fluorescence ratio detected will allow researchers to make comparative measurements of membrane potential and determine the percentage of mitochondria within a population that responds to an applied stimulus (12-15).
A recent study from our laboratory showed the ability of etoposide to induce alterations in the $\Delta\psi_{\text{m}}$ with the subsequent release of intermembrane space proteins (16, 17). The development of in vitro models for an adequate approach to neuroendocrine differentiation of prostatic carcinoma, and its implications in this disease, is imperative. In the present article, our research was based on the role of a representative neuropeptide, bombesin, in modulating the mitochondrial permeability transition alterations of cell death induced by etoposide on PC-3 cells, thus enforcing that the presence of the secretory products from neuroendocrine cells confers antiapoptotic capabilities on nonneuroendocrine cells in the androgen-insensitive prostatic PC-3 cancer cell line. On the other hand, the interaction between neuroendocrine cells and prostatic carcinoma cells is a novel model for the study of basic mechanisms of apoptosis. In this sense, new therapeutic protocols and trials need to be developed to test drugs acting through the neutralization of antiapoptotic intracellular pathways mediated by neuroendocrine hormones.

Materials and Methods

Cell Culture

Androgen-independent PC-3 cells (American Type Culture Collection, Manassas, VA) were grown in Ham’s F12 (Cambrex, Verviers, Belgium) supplemented with 10% fetal bovine serum (BioWhittaker, Verviers, Belgium) and 4% penicillin-streptomycin (Cambrex) in a water-saturated atmosphere of 5% CO$_2$ until the beginning of the experiments.

Treatment Administration

All experiments were started with unsynchronized exponentially growing cells. Treatment protocols for etoposide-induced apoptosis and inhibition of apoptosis by bombesin have been previously described by us (9, 18–22). Briefly, cells were seeded in glass-bottomed microplates (Willco wells; Amsterdam, the Netherlands) at a density of 200,000 cells per well and the culture medium was changed to 5% fetal bovine serum–supplemented medium (containing the floating apoptotic cells) followed by trypsinization of the rest of the monolayer (containing healthy cells). Both fractions were combined to reconstitute the total population and then centrifuged at 1,000 rpm for 5 min to get the pellet. Cells were then washed twice in PBS and cytospun by means of cytocentrifuges at 1,500 rpm for 5 min. Air-dried samples were stained for light microscopy (H&E) and fluorescence microscopy (fluorescent 4′,6-diamidino-2-phenylindole).

Cell Staining. For H&E staining, air-dried slides were fixed in 10% formaldehyde and stained in hematoxylin and counterstained with eosin. For fluorescent 4′,6-diamidino-2-phenylindole staining, air-dried slides were fixed in methanol at $-20^\circ\text{C}$ for 20 min, air-dried, and stained with 4′,6-diamidino-2-phenylindole (Serva, Boehringer-Ingelheim, Heidelberg, Germany) at room temperature for 20 min in the dark, and mounted with an antifading medium (O-phenylenediamine; Sigma) in glycerol (Merck, Darmstadt, Germany), and preserved at $-20^\circ\text{C}$ in the dark until examination, at a fluorescence range between 300 and 400 nm. The percentage of apoptotic cells was defined as the number of apoptotic cells / total cell number $\times 100$. At least 200 cells should be counted for each experiment.

Assessment of Apoptosis by AnnexinV

Cells were stained with Annexin V as recommended by the suppliers (Molecular Probes, Leiden, the Netherlands), conjugated with Alexa Fluor 594 for the evaluation of translocation of phosphatidylserine to the outer leaflet of the plasma membrane, and SYTOX Green (Molecular Probes) for nuclear staining, to a final concentration of 1 mmol/L. The SYTOX Green nucleic acid stain is a high-affinity nucleic acid stain that easily penetrates cells with compromised plasma membranes, and yet, will not cross the membranes of live cells. The SYTOX Green/DNA complex has excitation and emission maxima of 504 and
523 nm, respectively. Annexin V conjugated with Alexa Fluor 594 shows excitation and emission maxima of 590 and 617 nm, respectively. Briefly, after discarding the culture medium, cells were washed with cold PBS, and a staining solution with 80 µL of SYTOX Green solution in Annexin binding buffer and 20 µL of Annexin solution were added to a final volume of 100 µL of staining solution per well. Cells were incubated at 18°C to 24°C in the dark for 15 min, and then washed twice with Annexin binding buffer (supplied) prior to fixation for 10 min in 70% methanol and mounting with Vectashield (Vector Laboratories, Burlingame, CA). Cells were examined in an inverted confocal microscope Leica TCS-SL (Leica Microsystems, Barcelona, Spain).

Mitochondrial Permeability Potential

Cells were stained with the cationic dye JC-1 (MitoPT, Immunohistochemistry Technologies, Bloomington, MN), which exhibits potential-dependent accumulation in mitochondria. At low membrane potentials, JC-1 continues to exist as a monomer and produces a green fluorescence (emission at 527 nm). At high membrane potentials or concentrations, JC-1 forms J aggregates (emission at 590 nm) and produces a red fluorescence.

Staining Procedure. Cells were stained as recommended by the suppliers. Briefly, cells were cultured in glass-bottomed Willco wells for the assay, not exceeding a final amount of 10⁶ cells/mL, and after discarding the culture medium, 1× MitoPT staining solutions obtained from a 100× stock was added to the wells (0.5 mL/well). Cells were then incubated at 37°C for 15 min in a CO₂ incubator and, after discarding the medium, was washed twice with 1 to 2 mL of assay buffer warmed to 37°C. The wash was discarded and a drop of assay buffer was added to the wells prior to immediate examination in the inverted confocal microscope (Leica TCS SL), equipped with an HCX PL APO CS 40.0 × 1.25 oil immersion objective, with an incubation system consisting of a cube that completely covers the microscope and allows us to keep cells at 37°C in a controlled atmosphere with a mixed air/CO₂ flow of 4 L/h and 5% CO₂ during image collection and analysis.

Image Collection and Analysis

Images were collected and processed using the imaging software provided by the Leica TCS SL system. All samples were exposed to the laser for a time interval not more than 5 min to avoid photobleaching. JC-1 was excited at 490 nm.
Results

Characterization of the Apoptotic Process

Percentages of Apoptotic Cells. After 48 h of treatment with 100 μg/mL of etoposide, the percentage of apoptotic cells determined according to the examination of H&E, Annexin V, and 4',6-diamidino-2-phenylindole–stained cells was 61.7% in exposed cells and 7.1% in nontreated control cells. In PC-3 cells, the addition of bombesin resulted in a marked decrease of apoptosis (20.43% of apoptotic cells), whereas in the bombesin-treated group, 5.4% of the cells were apoptotic. Annexin V was used to confirm the induction of apoptosis using a confocal microscope.

Growth Kinetics and Cell Viability. All etoposide-treated groups presented worse viability than the control groups. The addition of neuropeptides resulted, as expected, in an increase in cell viability.

\[ \Delta \psi_{in} \] Assessment by Confocal Microscopy. Control cells showed heterogeneous staining of the cytoplasm with both red and green fluorescence coexisting in the same cell (Fig. 1A). Consistent with a mitochondrial localization, the red fluorescence was mostly found in rod-shaped and granular structures distributed throughout the cytoplasm. Although a minority of the mitochondria exhibited only green fluorescence; these were most conspicuous in areas of cytoplasm surrounding the nucleus. Treatment of PC-3 cells with bombesin increased the red fluorescence and frequent clusters of mitochondria were seen (Fig. 1B). Exposure of PC-3 cells to etoposide induced marked changes in \( \Delta \psi_{in} \) as evident from the disappearance of red fluorescence or the increase of green fluorescence in most cells, with a predominantly peripheral distribution. Some cells were devoid of red fluorescence, which is an indication of the loss of \( \Delta \psi_{in} \) and the severity of cell damage (Fig. 1C). Cell treatment with etoposide plus bombesin increased the red fluorescence in most cells, and protected cells which presented a similar distribution pattern to that observed in the control group, from the loss of \( \Delta \psi_{in} \) (Fig. 1D).

Statistical Analysis

Descriptive Analysis. For the variable ratio, which is equivalent to the quotient between the mean values of red and green pixels in each region of interest that corresponds to the variable cell area, significant differences (\( P < 0.00001 \)) between the four groups were found (Fig. 2).

Two-Way ANOVA. Using the quartiles of the variable area, four groups were established in the selected cells as a second factor was added which could affect the treatment, with a total of 16 groups, four defined by treatment and four defined by the areas, with four levels per group. Area influence on the red/green ratio between the four treatment groups, treatment influence on the red/green ratio related to area, and the red/green ratio differences depending on the cell area were assessed by means of a two-way ANOVA.

The ANOVA revealed a highly significant difference between the means of ratios between treatments (\( P = 0.000 \)), and the means of ratio for the area sizes (\( P = 0.000 \)),
and the interaction between treatments and area ($P = 0.0002$) was also highly significant, indicating that the differences between ratios of the area depend on the treatment. The assumptions of normality of the distribution in the 16 groups were satisfied (except for one group) and the Cochran’s C test for homogeneity of variance reported a significance level of >0.05 ($P = 0.12$), that is, we accept that the variances were not significantly different (Fig. 3). This is a strong interaction effect and is unlikely to be due to chance, as shown by ANOVA analysis. Post hoc contrasts were done for confirmation of the significance.

**Post hoc Comparisons.** The post hoc comparisons show the differences in model-predicted means for each pair of factor levels. In this case, because the interaction effect was significant, the differences between the different levels of treatment factor for each of the levels of the factor size were examined to contrast and estimate significant differences between the different treatments conditioned by the factor size. Due to the existence of a control group, the Dunnett test was used (Table 1). Furthermore, the HSD test of Tukey was used to contrast the pairwise differences between treatments (Table 2).

**Discussion**

The presence of neuroendocrine differentiation—understood as an exaggerated ratio of neuroendocrine cells to neoplastic epithelial cells in the prostate carcinoma—is associated with worse prognosis, higher tumor progression, and the androgen-independent status of the tumor, which becomes unresponsive to hormonal therapy, and has received increasing attention in recent years as a possible result of implications of therapy (1–4).

The putative function of neuroendocrine cells in stimulating proliferation and/or inhibiting the apoptotic process, worsening the prostate cancer outcome through a paracrine hormonal mechanism, provides a rationale for the experimental use of drugs which could inhibit the secretion of neuroendocrine products, the aim of which is to counteract tumor progression (6–8, 23–25). In the present article, our research was based on the role of bombesin in modulating the induction of mitochondrial membrane potential alterations in etoposide-induced cell death in an androgen-independent PC-3 prostate cancer cell line.

In apoptosis, mitochondria have two essential functions. First, to provide energy in the form of ATP, which is

**Table 1. Differences between each treatment group and control group with 95% confidence interval showing the influence of size**

<table>
<thead>
<tr>
<th>Treatment A</th>
<th>Treatment B</th>
<th>Mean differentiation (A-B)</th>
<th>$P$</th>
<th>95% Confidence intervals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size 1 Bombesin</td>
<td>Control</td>
<td>0.2142</td>
<td>0.170</td>
<td>-0.0655 - 0.4939</td>
</tr>
<tr>
<td>Etoposide</td>
<td>Control</td>
<td>-0.4397*</td>
<td>0.000</td>
<td>-0.7024 - 0.1770</td>
</tr>
<tr>
<td>Etoposide + bombesin</td>
<td>Control</td>
<td>0.1629</td>
<td>0.460</td>
<td>-0.1528 - 0.4787</td>
</tr>
<tr>
<td>Size 2 Bombesin</td>
<td>Control</td>
<td>0.6995*</td>
<td>0.000</td>
<td>0.4575 - 0.9416</td>
</tr>
<tr>
<td>Etoposide</td>
<td>Control</td>
<td>-0.1700</td>
<td>0.183</td>
<td>-0.3966 - 0.0565</td>
</tr>
<tr>
<td>Etoposide + bombesin</td>
<td>Control</td>
<td>0.3694*</td>
<td>0.005</td>
<td>0.0956 - 0.6431</td>
</tr>
<tr>
<td>Size 3 Bombesin</td>
<td>Control</td>
<td>0.4509*</td>
<td>0.000</td>
<td>0.2148 - 0.6871</td>
</tr>
<tr>
<td>Etoposide</td>
<td>Control</td>
<td>-0.2974*</td>
<td>0.005</td>
<td>-0.5184 - 0.0763</td>
</tr>
<tr>
<td>Etoposide + bombesin</td>
<td>Control</td>
<td>-0.0830</td>
<td>0.792</td>
<td>-0.3501 - 0.1841</td>
</tr>
<tr>
<td>Size 4 Bombesin</td>
<td>Control</td>
<td>0.6311*</td>
<td>0.000</td>
<td>0.4159 - 0.8463</td>
</tr>
<tr>
<td>Etoposide</td>
<td>Control</td>
<td>-0.0890</td>
<td>0.581</td>
<td>-0.2909 - 0.1129</td>
</tr>
<tr>
<td>Etoposide + bombesin</td>
<td>Control</td>
<td>-0.0028</td>
<td>1.000</td>
<td>-0.2461 - 0.2406</td>
</tr>
</tbody>
</table>

*Significant differences.
required for cells to die by the apoptotic pathway. Second, to release proapoptotic proteins normally sequestered in the intermembrane space into the cytosol, in which they trigger downstream apoptotic signaling pathways (26–30).

Detection of the mitochondrial permeability transition event provides an early indication of the initiation of cellular apoptosis. This process is typically defined as a sudden loss of mitochondrial membrane potential, as measured by the change in the mitochondrial Δψm, indicative of apoptosis, can be detected with JC-1. JC-1 was incorporated (for easy penetration) into cells and healthy mitochondria, in which it aggregates and fluoresces green (590 nm). When the mitochondrial Δψm collapses in apoptotic cells, the reagent no longer accumulates inside the mitochondria, and instead, it is distributed throughout the cell. When dispersed in this manner, it assumes a monomeric form which fluoresces green (527 nm; refs. 11, 35–37).

A loss of Δψm leads to the induction of apoptosis in etoposide-treated PC-3 cells and this damage is prevented by bombesin. The quantitative analysis of JC-1–stained cells revealed a significant decrease in the red (high Δψm) to green (low Δψm) ratio in etoposide-treated cells compared with control cells, which was restored in the presence of bombesin. In bombesin-treated cells, an increase in the ratio was observed. Signal transduction molecules activated by bombesin include phosphoinositide-3-kinase/Akt, with subsequent activation of transcription factors (38, 39), whereas the Akt pathway has been involved in the regulation of Δψm as well as cell size (40).

The interaction between treatments and area (P = 0.0002), indicating that the difference between ratios of area depends on treatment, is highly significant. Data obtained for etoposide-treated cells confirm that PC-3 cells keep their apoptotic machinery, showing an apoptotic volume decrease in response to etoposide (41). The channel activation leads to a significant decrease in potassium content, and a significant increase in sodium (42–44). The variation in cellular volume was evaluated using the sum of the sodium and potassium contents (45). In previous studies, we have shown that etoposide-treated cells passed through a series of morphologically identifiable stages in their pathway to death. A progressive decrease of intracellular potassium, as cells progress through the different stages, with a dramatic lowering in the final stage (20, 22).

Combined treatment with etoposide and bombesin resulted in a modulation of the apoptotic response with a decrease in apoptosis, and an increase in cell viability even with respect to control cells. The differences in treatment factors vary for each size group. Clear differences were found for size 1 cells between bombesin-treated cells, etoposide plus bombesin–treated cells, and control cells.

### Table 2. Pairwise differences between the four groups with 95% confidence interval

<table>
<thead>
<tr>
<th>Treatment A</th>
<th>Treatment B</th>
<th>Mean differentiation (A-B)</th>
<th>P</th>
<th>95% Confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>Bombesin</td>
<td>−0.2142</td>
<td>0.275</td>
<td>−0.5223</td>
</tr>
<tr>
<td>Etoposide*</td>
<td>Etoposide*</td>
<td>0.4397</td>
<td>0.001</td>
<td>0.1503</td>
</tr>
<tr>
<td>Etoposide+ bombesin</td>
<td>Etoposide+ bombesin</td>
<td>−0.1629</td>
<td>0.618</td>
<td>−0.5108</td>
</tr>
<tr>
<td>Bombesin</td>
<td>Etoposide*</td>
<td>−0.6539</td>
<td>0.000</td>
<td>0.3951</td>
</tr>
<tr>
<td>Etoposide + bombesin</td>
<td>Etoposide + bombesin</td>
<td>0.0513</td>
<td>0.976</td>
<td>−0.2716</td>
</tr>
<tr>
<td>Etoposide</td>
<td>Etoposide + bombesin*</td>
<td>−0.6026</td>
<td>0.000</td>
<td>−0.9077</td>
</tr>
<tr>
<td>Size 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>Bombesin*</td>
<td>−0.6995</td>
<td>0.000</td>
<td>−0.9660</td>
</tr>
<tr>
<td>Etoposide</td>
<td>Etoposide</td>
<td>0.1700</td>
<td>0.292</td>
<td>−0.0794</td>
</tr>
<tr>
<td>Etoposide+ bombesin</td>
<td>Etoposide + bombesin*</td>
<td>−0.3694</td>
<td>0.009</td>
<td>−0.6708</td>
</tr>
<tr>
<td>Bombesin</td>
<td>Etoposide*</td>
<td>0.8696</td>
<td>0.000</td>
<td>0.6445</td>
</tr>
<tr>
<td>Etoposide + bombesin*</td>
<td>Etoposide + bombesin*</td>
<td>0.3301</td>
<td>0.014</td>
<td>0.0486</td>
</tr>
<tr>
<td>Etoposide</td>
<td>Etoposide + bombesin*</td>
<td>−0.5394</td>
<td>0.000</td>
<td>−0.8049</td>
</tr>
<tr>
<td>Size 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>Bombesin*</td>
<td>−0.4509</td>
<td>0.000</td>
<td>−0.7109</td>
</tr>
<tr>
<td>Etoposide*</td>
<td>Etoposide*</td>
<td>0.2974</td>
<td>0.010</td>
<td>0.0540</td>
</tr>
<tr>
<td>Etoposide + bombesin</td>
<td>Etoposide + bombesin</td>
<td>0.0830</td>
<td>0.884</td>
<td>−0.2111</td>
</tr>
<tr>
<td>Bombesin</td>
<td>Etoposide*</td>
<td>0.7483</td>
<td>0.000</td>
<td>0.5287</td>
</tr>
<tr>
<td>Etoposide + bombesin*</td>
<td>Etoposide + bombesin*</td>
<td>0.5339</td>
<td>0.000</td>
<td>0.2592</td>
</tr>
<tr>
<td>Etoposide</td>
<td>Etoposide + bombesin*</td>
<td>−0.2144</td>
<td>0.143</td>
<td>−0.4734</td>
</tr>
<tr>
<td>Size 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>Bombesin*</td>
<td>−0.6311</td>
<td>0.000</td>
<td>−0.8680</td>
</tr>
<tr>
<td>Etoposide</td>
<td>Etoposide</td>
<td>0.0890</td>
<td>0.727</td>
<td>−0.1332</td>
</tr>
<tr>
<td>Etoposide + bombesin</td>
<td>Etoposide + bombesin</td>
<td>0.0028</td>
<td>1.000</td>
<td>−0.2651</td>
</tr>
<tr>
<td>Bombesin</td>
<td>Etoposide*</td>
<td>0.7201</td>
<td>0.000</td>
<td>0.5195</td>
</tr>
<tr>
<td>Etoposide + bombesin*</td>
<td>Etoposide + bombesin*</td>
<td>0.6338</td>
<td>0.000</td>
<td>0.3836</td>
</tr>
<tr>
<td>Etoposide</td>
<td>Etoposide + bombesin*</td>
<td>−0.0863</td>
<td>0.780</td>
<td>−0.3227</td>
</tr>
</tbody>
</table>

*Significant differences.
with respect to etoposide-treated cells. For size 2 cells, differences were found between bombesin- and etoposide plus bombesin–treated cells with respect to control and etoposide-treated cells. For sizes 3 and 4, bombesin-treated cells showed a higher ratio than cells in the other three groups. The differences between treatments were remarkable in the control and etoposide plus bombesin–treated cells, but not in etoposide-treated cells and cells exposed to bombesin alone. If there were no interaction effects, the lines in the figures would be parallel. This is a positive fact which confirms the experimental design, and that these data support the role of bombesin as a growing factor (46, 47). The protection by bombesin against etoposide-induced loss of Δψm, as shown in this study, occurs by the inhibition of apoptosis and maintenance of mitochondrial integrity.

Our evidence shows that the presence of neuroendocrine cells and their secretory products confers antiapoptotic capabilities on nonneuroendocrine cells in androgen-insensitive prostatic cancer cells. New therapeutic protocols and trials need to be developed to test drugs acting through the neutralization of antiapoptotic intracellular pathways mediated by neuroendocrine hormones. Hopefully, this will lead to the development of entirely new therapeutic approaches in hormone refractory prostate cancer.

References

11. Salvioni S, Ardizzone A, Franceschi C, Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescence probe to assay Δψm changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997;411:77 – 82.


Molecular Cancer Therapeutics

Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells

Mercedes Salido, Juan L. Gonzalez and Jose Vilches


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/6/4/1292

Cited articles
This article cites 45 articles, 5 of which you can access for free at:
http://mct.aacrjournals.org/content/6/4/1292.full.html#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
/content/6/4/1292.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.